Jinxin Technology Holding Company NAMI
Regular-session close
After hours · Nov 13, 4:00 PM ET
- YTD
- -91.05%
- 1 year
- -90.14%
Fundamental scorecard
4 of 25 checks passed on NAMI’s reported financials
4of 25 checks passed
- Value 0 of 5
- Growth 1 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Jun 30, 2026.
Value 0 of 5
- Failed:P/E below its own 5-year median No profit over FY 2025, so no P/E.
- Failed:P/E under 20 No profit over FY 2025, so no P/E.
- No data:Price to sales below its own 5-year median Price to sales 0.1. Not enough data to decide.
- No data:Price to book below its own 5-year median Price to book 0.6. Not enough data to decide.
- Failed:Free cash flow yield above 4% Free cash flow of -25.4M is -57.5% of the market value.
Growth 1 of 5
- Passed:Revenue grew over the last year Revenue of 413M is +1.6% on the year before.
- No data:Revenue grew more than 5% a year over five years Not enough data to decide.
- Failed:Earnings per share grew over the last year EPS -31.50 against 18.00 in the year before.
- No data:Earnings per share grew more than 5% a year over five years Not enough data to decide.
- Failed:Analysts expect higher earnings per share over the next year The average forward estimate is -100.0% on the last 12 months.
Profitability 0 of 5
- Failed:Profitable over the last year Net income of -94.3M over FY 2025.
- Failed:Profitable in each of the last five fiscal years A profit in 3 of the last 5 fiscal years.
- Failed:Return on equity above 15% Return on equity of -89.9%.
- Failed:Net margin above its 5-year average Net margin of -22.8% against a 5-year average of -1.9%.
- Failed:Free cash flow is at least 80% of net income No profit over FY 2025 to compare with.
Financial health 3 of 5
- Passed:Short-term assets cover short-term liabilities Short-term assets of 122M against short-term liabilities of 81.5M.
- Passed:Short-term assets cover long-term liabilities Short-term assets of 122M against long-term liabilities of 2.70M.
- Passed:Net debt under 40% of equity More cash than debt: 58.6M of cash against 13.6M of debt.
- Failed:Operating cash flow covers at least 20% of debt Operating cash flow of -24.6M is -180.3% of debt.
- Failed:Operating profit covers interest at least 3 times Operating profit is -2944.3 times the interest expense.
Dividend 0 of 5
- Failed:Pays a dividend No dividend paid.
- Failed:Yield above 1.5% No dividend paid.
- Failed:Pays out under 75% of profit No dividend paid.
- Failed:Covered by free cash flow No dividend paid.
- Failed:Not cut in the last five fiscal years No dividend paid.
Mechanical checks on reported financials against fixed thresholds. They describe the numbers; they are not a recommendation to buy or sell. Amounts are in the company’s reporting currency.
Included in Essentials and up
Sign in to see Fair value
Discounted cash flow estimates against the price, and the P/E against its industry and sector.
Included in Essentials and up
Sign in to see Head count and owner earnings
Employees by annual report and the cash the business earns for its owners.
Financial position
What NAMI owns and owes, as of Jun 30, 2026
Short term and long term
Balance sheet · 187M of assets
Debt, equity and cash by year
Now: 45.0M more cash than debt
- Equity
- Debt
- Cash
Fiscal years, then the newest quarter. Cash includes short-term investments.
From the company’s SEC filings, in its reporting currency.
Cash flow and returns
How NAMI’s profit turns into cash, and what its capital earns
From profit to free cash flow · FY 2025
Returns on capital · FY 2025
-
-89.9%
Return on equity
Below the 15% mark · Profit per dollar of shareholders’ equity
-
-43.8%
Return on assets
Below the 5% mark · Profit per dollar of everything it owns
-
-89.1%
Return on capital employed
Below the 10% mark · Operating profit per dollar of long-term capital
From the company’s SEC filings, in its reporting currency. The tick on each dial is a common rule-of-thumb level, not a target.
Financial health
Altman Z-Score
-1.13 Distress zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
4 / 9 Average
Nine pass/fail tests of profitability, leverage and efficiency.
Rating
C+2 / 5 overall
- DCF 1
- Return on Equity 1
- Return on Assets 1
- Debt / Equity 4
- P/E 1
- P/B 4
Valuation
Profitability
Growth (YoY)
Financial Health
Dividends
Annual · latest fiscal year ends 2025-12-31
